Johnson & Johnson CEO: America's innovation advantage in healthcare is accelerating, with U.S. companies driving 55% of global biopharmaceutical R&D

American companies drive 55% of global R&D in biopharmaceuticals and produce more new medicines than any other country. Roughly 70% of new medicines launch first in the U.S., giving Americans access to breakthrough treatments months, often years, ahead of other countries.

Artificial intelligence is accelerating healthcare progress by transforming how scientists discover medicines, design clinical trials, and match therapies to patients. AI automates routine tasks so clinicians can spend more time listening to patients, rather than replacing human judgment in healthcare.

Johnson & Johnson committed more than $55 billion over the next four years to expand U.S. R&D, manufacturing, and technology, with the vast majority of its most advanced medicines made in America.